Perceptive Xontogeny Venture
Venture capitalNew York · 1 people tracked
Also known as Perceptive Xontogeny Venture SLP
Find your way into Perceptive Xontogeny Venture
Fund manager profile
Perceptive Xontogeny Venture is a venture fund manager based in New York. SEC filings show 4 venture funds on record, most recently Perceptive Xontogeny Venture Fund II, LP ($515M offering) filed May 2021.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 1 people
from public directoriesWhat they invest in
from 12 of 12 portfolio companiesBiotech ×9Healthtech ×6Medical Devices ×3AI & Machine Learning ×2Digital Health ×2Cleantech ×1Climate Tech ×1EdTech ×1
HQs:United States×8
Investments · 12 tracked
founders shown can be your intro pathBy year:2025 · 32024 · 12023 · 12021 · 16 dated
Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
BiotechHealthtechMedical Devices
Michael Henderson(Chief Executive Officer and Director)in
Co-investorsAccess BiotechnologyRA CapitalRTW Investments L.P.Venrock Healthcare Capital Partners
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersRiverVest Venture Partners+8 more
Biopharmaceutical company using computational biology to identify and develop novel peptide therapies, including AXT107 for retinal/eye diseases.
BiotechBethesda, US
Aleksander S. Popel, PhD(Executive Officer, Director)Jordan J. Green(Executive Officer, Director)inWendy Perrow(Executive Officer, Director)in
Co-investorsRapha Capital Management, LLC
Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.
BiotechSan Mateo, US
Gina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)
BoardAbraham Bassan(Director)
Co-investorsNextech InvestRed Tree VentureSamsara BioCapitalAlly Bridge GroupJanus Henderson InvestorsThird Rock Ventures
Delve develops molecular next-generation sequencing (mNGS) tests that diagnose infections in cerebrospinal fluid and other clinical samples, enabling rapid pathogen identification for patients with difficult-to-diagnose infections.
AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices
Dr. Joseph DeRisi(Founder)
Co-investorsGV (Google Ventures)Section 32
Galvanize provides customized technical education and training programs to help enterprise teams build skills in AI, machine learning, XP and Agile practices, data pipelines, and cloud operations.
AI & Machine LearningEdTechEnterprise SoftwareFuture of WorkDenver, US
Christopher C. Onan(Executive Officer)James Deters(President and Chief Executive Officer)Lawrence Mandes(Managing Director, New Markets)in
BoardDaniel Pianko(Director)Tatiana Goldstein(Director)Jerrold Miller(Director)
Co-investorsSofinnova PartnersTeamworthy VenturesThe Colorado Impact FundVTF CapitalAlly Bridge GroupCatalyst Investors+5 more
Galvanize Climate Solutions is an investment firm focused on the energy transition, deploying capital across areas such as climate risk analytics and clean energy.
CleantechClimate TechEnergy
Veery Maxwell(Founder)in
Co-investorsBlue Haven InitiativeGalvanize Climate SolutionsABS Capital PartnersAlly Bridge GroupFidelity InvestmentsGilmartin Capital LLC+4 more
Galvanize Therapeutics develops surgical ablation technology using its proprietary Aliya Pulsed Electric Field (PEF) energy to destroy soft tissue cells through regulated cell death mechanisms.
BiotechHealthtechMedical DevicesRedwood City, US
Doug Godshall(Executive Officer, Director)inSteve Anheier(Executive Officer)in
BoardJonathan Waldstreicher(Executive Officer)Antoine Papiernik(Director)inSeth Harrison(Director)Zack Scott(Director)in
Co-investorsNorwest Venture PartnersAlly Bridge GroupATPFidelity InvestmentsGilmartin Capital LLCJanus Henderson Investors+2 more
HealthtechSan Diego, US
Jim Chauvapun(Executive Officer, Director)Dirk van den Boom(Executive Officer, Director)
BoardFrederick Callori(Director)Chris Garabedian(Director)
Tellus Therapeutics is a biopharmaceutical company developing therapeutics.
BiotechDigital HealthHealthtechHillsborough, US
Eric Benner, M.D., Ph.D.(Acting CSO and Co-founder)Jason Kralic, Ph.D.(CEO and Co-founder)Simon Gregory, Ph.D.(Scientific Co-Founder and Scientific Advisory Board Member)Jason E. Karlic(Executive Officer, Director)Alex M. Ruckdaeschel(Director)Eric J. Benner(Executive Officer, Director)
TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates and monoclonal antibodies for cancer, including lead candidate TORL-1-23 targeting CLDN6 in ovarian cancer.
BiotechCulver City, US
Mark Alles(Executive Officer, Director)Mark Attanasio(Director)David Licata(Executive Officer, Director)Neil O'Brien(Director)Amit Sinha(Director)Lynn Seely(Director)
Co-investorsOCV PartnersRA CapitalCowen Healthcare InvestmentsGoldman SachsVertex Ventures HC
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Exits · 2
2 IPOsApogee TherapeuticsNASDAQ: APGEAvalyn Pharma IncNASDAQ: AVLN
Portfolio news
latest coverage across their companies
Galvanize · muonspace.com · Aug 20, 2026
Avalyn Pharma Inc · investing.com · May 1, 2026
Delve Bio · bitscale.ai · Mar 11, 2026
Torl Bio · endpoints.news · Oct 7, 2025
Galvanize Therapeutics · fiercebiotech.com · Sep 4, 2025
CARGO Therapeutics · finance.yahoo.com · Jul 29, 2025
IPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Apogee Therapeutics | 3.4% | $62.00 | Mar 2024 | $122.6M |
| Avalyn Pharma Inc | 5.4% | $18.00 | Apr 2026 | $40.5M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Perceptive Xontogeny Venture made?
- Perceptive Xontogeny Venture has 12 tracked investments, 2 of which have exited, including 3 dated in the last 24 months.
- Where is Perceptive Xontogeny Venture located?
- Perceptive Xontogeny Venture is headquartered in New York, US.